Chemed Corp Liquidation Value

CHE Home Healthcare

Cash & Equivalents

$16.86M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $16.86M
Total Obligations: -$662.80M
$-645.94M
Per share: $-47.24
Period: 2026-03-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $16.86M
AR: $215.48M
Total Obligations: -$662.80M
$-430.46M
Per share: $-31.48
Period: 2026-03-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $16.86M
AR: $215.48M
Inventory: $7.21M
Total Obligations: -$662.80M
$-423.25M
Per share: $-30.95
Period: 2026-03-31

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-645.94M$-47.24
Liquid Liquidation Value$-430.46M$-31.48
Operating Liquidation Value$-423.25M$-30.95

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-04-28. View on SEC EDGAR →

Cash & Equivalents$16.86M
Accounts Receivable$215.48M
Inventory$7.21M
Current Liabilities$321.42M
Long-term Debt (?)$91.20M
Op. Lease Liability (?)$104.45M
Finance Lease (?)$0
Shares Outstanding13.7M

Explore all 133 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$16.86M$215.48M$7.21M$65.70M$321.42M$91.20M$104.45M$0
2025-12-31$74.52M$182.57M$7.54M$64.46M$287.13MN/A$102.87MN/A
2025-09-30$129.75M$215.57M$8.24M$48.09M$292.04MN/A$99.46M$0
2025-06-30$249.90M$184.88M$9.15M$50.86M$263.89MN/A$101.86M$0
2025-03-31$173.88M$285.87M$7.79M$47.69M$290.56MN/A$102.08M$0
2024-12-31$178.35M$171.16M$8.19M$44.15M$285.69MN/A$98.54MN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-04-28 View
2025-12-31 10-K 2026-02-27 View
2025-09-30 10-Q 2025-10-31 View
2025-06-30 10-Q 2025-07-31 View
2025-03-31 10-Q 2025-04-28 View
2024-12-31 10-K/A 2025-04-01 View
2024-12-31 10-K 2025-02-28 View
2024-09-30 10-Q 2024-11-01 View

AI Insights

AI Insight·Generated 2026-05-05

Chemed Corp (CHE) operates two segments: VITAS (hospice, ~90% of revenue) and Roto-Rooter (plumbing/drain services). Under a liquidation lens, recovery to equity is deeply negative and worsening, consistent with MFFAIS-reported values of approximately -$500M (CLV), -$285M (LLV), and -$278M (OLV) at March 31, 2026. The balance sheet is dominated by intangible assets that recover zero in liquidation: goodwill of $687.5M and other intangibles net of $80.4M together represent approximately 50% of reported total assets of $1.54B. Applied haircuts—PP&E at 50-70% on $207.7M book, AR at 90-95% on $215.5M, cash at 100% on $16.9M, inventory at 60% on $7.2M—produce a recoverable asset pool well below total liabilities of $687.8M at face. The liability stack includes operating lease obligations with remaining undiscounted payments of $162.4M (present value $145.7M), long-term debt of $91.2M on the revolver (drawn up from zero at December 31, 2025, per narrative; $135.5M drawn and $44.3M repaid in Q1 2026), deferred compensation liability of $142.7M (roughly offset by plan assets of $143.8M but legally separate obligations), defined benefit pension cost accruing at $9.9M per quarter, and current liabilities of $321.4M. The revolver draw is the most notable change from the prior filing: the filing confirms zero variable rate debt at March 31, 2026, but the cash flow statement shows net draws of $91.2M in Q1 2026 to fund $190M in share repurchases plus $20.6M in acquisitions. The February 2026 board authorization of an additional $300M under the repurchase program, combined with 500,000 shares repurchased at $395.36 in March 2026 ($197.7M TreasuryStockValueAcquiredCostMethod for the quarter per XBRL, though item 2(c) shows $197.7M spent in March alone against a weighted average of $395.36), accelerated the conversion of equity into treasury stock. Treasury stock now stands at $3.81B cumulative cost basis against retained earnings of $3.01B—book equity of $848M is sustained only by $1.60B of additional paid-in capital. The accounts receivable days outstanding (excluding unapplied Medicare payments) deteriorated sharply from 38.7 days in the prior period to 38.8 days currently, while estimated uncollectible accounts as a percent of revenues doubled from 0.6% to 1.2%, modestly pressuring AR recovery assumptions. Goodwill increased by $20.5M due to acquisitions in Q1 2026. No pension obligation reset or lease restructuring was disclosed. The filing does not separately tag the defined benefit pension liability in XBRL; it appears only in MD&A/footnote disclosure.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...